HFpEF: Demonstrate the Syndrome

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Confirm HFpEF, define the comorbid phenotype, and link treatment to supported outcomes with a practical monitoring plan.

Preserved EF can coexist with high filling pressure. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Preserved EF can coexist with high filling pressure. . An ejection fraction alone does not establish HFpEF. Connect symptoms to objective cardiac evidence. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

A multisystem syndrome

HFpEF combines symptoms and signs of heart failure with evidence of abnormal filling pressures or related cardiac dysfunction. Preserved ejection fraction alone is insufficient.

Recognize contributors

Obesity, hypertension, diabetes, atrial fibrillation, CKD, and pulmonary disease can shape the phenotype and mimic or aggravate symptoms.

Require more than preserved EF

In a breathless patient, assess natriuretic peptides and echocardiographic structural/diastolic findings alongside congestion. Obesity can lower natriuretic peptides; atrial fibrillation and CKD can raise them. A normal resting study may leave exercise-related filling-pressure elevation unresolved.

Escalate uncertain cases

Exercise or invasive hemodynamic testing may help when resting studies do not explain exertional symptoms and the result would change management.

Manage the phenotype

Treat congestion and contributing conditions, improve functional capacity, and apply therapies supported in the appropriate population. Monitor kidney function and potassium.

Treat the demonstrated phenotype

Treat congestion with diuretics while assessing BP and kidney response. Address atrial fibrillation, obesity, sleep apnea, ischemia, and hypertension when present. Consider an SGLT2 inhibitor for appropriate symptomatic HFpEF; a therapy’s benefit for HF events should not be relabeled as proof of reversing all kidney disease.

Continue learning